Search results


Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
You searched for:
Results: 24

Respiratory diseases

Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterised by a reduction in the respiratory flow although they are...


Normally, delivery takes place between the 37th and the 42nd week of gestation. By that time, the foetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the neonate is...

Rare diseases

The term rare applies to those diseases affecting a limited number of people with a prevalence below a given cut-off point, which is codified by the legislation of each individual country. The EU sets this threshold at 0.05% of the population, i.e. one case for every 2,000 inhabitants (in the US a...


Piroxicam-beta-cyclodextrin is a molecule developed by Chiesi, based on a chemical complex created by host-guest technology, in which each molecule of piroxicam is coated with a molecule of starch. This formulation leads to significantly improved resorption and thus to a much faster onset of...


The history of the Chiesi company is the history of a personal dream that became collective: “To create innovative tools with which to provide effective treatment”. For more information - Chiesi Group and Chiesi Central Eastern Europe (Chiesi Pharmaceuticals...



Chiesi Bulgaria

Chiesi Bulgaria is a part of an international Group focusing on research, which develops and offers innovative pharmaceutical solutions of added value aimed at improving patients' quality of life.   We have always adhered to a series of corporate values in the pursuit of our company...



Annual report


Chiesi in the World


Therapeutical Areas


Code of ethics, compliance and disclosure

Ethics & Compliance / Code of Ethics & Compliance   The Code of Ethics and Compliance expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical...

Patient organisations

List of Patient Organizations supported by Chiesi Bulgaria   in 2015:   Association “Organization of Thalassemia Patients in Bulgaria”   Partial support of the Organization of Thalassemia Patients in Bulgaria (OTPB) in conducting activities on the occasion of the...

Working at Chiesi

  Your career opportunity   It is the personnel that make a company what it is. Our employees are critical factors in the success of our company. Our team is characterized by personal commitment, experience and clear identification with the Group’s corporate values. Although we...


The following contact details must to be used for comments or questions concerning our Company and cannot be used to report adverse event to our products or for medical questions. For this kind of reporting, please  refer to PHARMACOVIGILANCE

Legal information

Company name:      Chiesi Bulgaria Ltd. Managing Director:  George Krastev, Mag. Pharm. Principal office:      83 Gyueshevo Str., Business Centre Serdika, Ofiice 104, 1330 Sofia, Bulgaria Co. Reg. No:...


Chiesi Bulgaria Ltd. has prepared the information contained on this website from various internal and external sources with due professional care. All information on this webpage is intended for health care professionals and contacts. For more information get in touch with our team.   Please...


Chiesi has a system of pharmacovigilance to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate action when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicines is continually evaluated. When...

Search result





Data privacy statement We are pleased about your visit to our website and your interest in our company and our products. We respect the privacy of all those who visit this website. Chiesi Bulgaria Ltd. is aware of the sensitivity of information and personal data in the area of pharmaceuticals and...


  This project was edited and produced by Dynamic Mind.

Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic

  The Group commits €3 million for donations to support the ongoing emergency in Italy Sustained efforts designed to ensure continuity of supply-chain and production despite increased restrictions in Italy and around the world Company also announces a €1 million investment in...

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).

  CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an...